Overview
- Phrontline closed a $60 million Pre-A+ round led by Lapam Investment, joined by Samsung Venture Investment Corporation and other new and existing backers.
- Samsung’s Life Science Fund will invest in Phrontline, according to Samsung and Yonhap, with financial terms undisclosed.
- The company says the funding will accelerate clinical and preclinical ADC programs and support broader global operations.
- Lead asset TJ101, a bispecific EGFR/B7-H3 ADC, is enrolling patients in parallel first-in-human studies in China and the United States.
- Recent deals include a Samsung Bioepis collaboration to co-develop two bispecific, dual-payload ADCs and an exclusive TJ101 license in Mainland China and Hong Kong to Sino Biopharmaceutical with upfront, milestone and royalty components.